William A. Sullivan's departure as Chief Financial Officer of Zivo Bioscience, Inc. was reported; the filing names no successor. As of November 6, 2026, Zivo Bioscience, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 30, 2026, naming 2 departures (Form 8-K, March 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Zivo Bioscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Zivo Bioscience, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-30. It names 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Zivo Bioscience, Inc. files it.
Also on the record for Zivo Bioscience, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 27, 2026 | Stake report, Schedule 13D/A, by Mark E. Strome | 12.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zivo Bioscience, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Zivo Bioscience, Inc. and the records around it.
Zivo Bioscience, Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
Companies that share a holder
- Mark E. Strome also filed stake reports on 2 other companies: Cue Biopharma, Inc. (Oct 2026), HeartBeam, Inc. (Aug 2026)
Watch Zivo Bioscience, Inc.
Get an email when Zivo Bioscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zivo Bioscience, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Zivo Bioscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zivo Bioscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-30 | Out | Chief Financial Officer | 8-K, 2026-03-30 | ||
| 2026-03-30 | Out | Director | 8-K, 2026-03-30 |
Who leads Zivo Bioscience, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Alison A. Cornell, departure reported (filed 2026-03-30). No successor is named in these filings.
- Chief Financial Officer: William A. Sullivan, departure reported (filed 2026-03-30). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Zivo Bioscience, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Zivo Bioscience, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Zivo Bioscience, Inc.Every change, in the filing's words
Departing: William A. Sullivan, Chief Financial Officer
On March 26, 2026, William A. Sullivan announced his intention to resign as Interim Chief Financial Officer of Zivo Bioscience, Inc. (the "Company"), effective Monday, March 30, 2026.
Departing: Alison A. Cornell, Director
March 26, 2026, Ms. Alison A. Cornell notified the Board of Directors of Zivo Bioscience, Inc. of her decision to resign as a member of the Board of Directors and all committees of the Board, effective immediately.
- Ms. Cornell served as a member of the Compensation, Nominating and Audit Committees.
- The resignations of Mr. Sullivan and Ms. Cornell are made in connection with the Company's cost-cutting measures, including its decision to deregister its securities and cease public reporting, and do not result from any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- The Board of Directors and the Company thank Mr. Sullivan and Ms. Cornell for their service and contributions to the Company during their tenures.
Tools for this story
Each opens in a new tab, filled in for Zivo Bioscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.